Stockscreener 앱 받기
0.6505
1.28%
0.0082
시간 외 거래:
.72
0.0695
+10.68%
Femasys Inc 주식(FEMY)의 최신 뉴스
Returns Recap: Does Ares Management Corporation meet Warren Buffetts criteria2025 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
Femasys Receives Nasdaq Extension to Regain Listing Compliance - TipRanks
Femasys granted 180-day extension by Nasdaq to meet minimum bid price rule - Investing.com
Femasys Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Stock Recap: Will FUFU benefit from geopolitical trendsCPI Data & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Sahm
Femasys receives 180-day Nasdaq extension to meet minimum bid price - Investing.com Nigeria
Femasys receives 180-day Nasdaq extension to meet minimum bid price By Investing.com - Investing.com South Africa
Femasys secures Nasdaq extension to regain bid price compliance - MSN
Nasdaq gives Femasys more time to fix sub-$1 share price by July 2026 - Stock Titan
Femasys partners with Refuah Health Center to expand FemaSeed fertility treatment - Investing.com Nigeria
Dow Update: Why Femasys Inc stock attracts global investorsTrade Volume Summary & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Femasys Inc. Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed®? in Community-Based Care - marketscreener.com
Femasys Inc. Partners with Refuah Health Center to Enhance Accessibility of FemaSeed for Infertility Treatment - Quiver Quantitative
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - The Manila Times
Community clinic partnership brings first-line FemaSeed fertility care closer - Stock Titan
Will Femasys Inc. stock maintain growth storyGap Up & Reliable Breakout Stock Forecasts - Улправда
What valuation multiples suggest for Femasys Inc. stockJuly 2025 Update & Safe Capital Growth Stock Tips - Улправда
Published on: 2026-01-09 05:32:45 - Улправда
Can Femasys Inc. stock rebound after recent weaknessPortfolio Return Report & Expert Approved Trade Ideas - Улправда
How Femasys Inc. stock performs after earnings2025 Price Momentum & Weekly High Momentum Picks - Улправда
Jonathan Schechter buys PharmaCyte Biotech shares worth $48,232 By Investing.com - Investing.com Nigeria
How Femasys Inc. stock reacts to inflationary pressures2026 world cup usa national team group stage goalkeepers counter attacking expert forecast guide - ulpravda.ru
Earnings Beat: Will MARZ stock keep high P E multiples2025 Biggest Moves & Pattern Based Trade Signal System - moha.gov.vn
Femasys gains UK approval for women's health products - MSN
Market Leaders: How strong is Femasys Inc stock balance sheetQuarterly Earnings Summary & AI Forecast for Swing Trade Picks - Bộ Nội Vụ
User | theeveningleader.comFemasys Inc.Common Stock (Nasdaq:FEMY) Stock Quote - FinancialContent
Femasys files for at-the-market offering of up to $9.8 million in common stock - Investing.com Australia
Femasys Launches At-the-Market Common Stock Offering - TipRanks
Femasys files for at-the-market offering of up to $9.8 million in common stock By Investing.com - Investing.com South Africa
Suwanee company Femasys Inc. gets FDA approval for diagnostic device - The Business Journals
Contemporary OB/GYN week in review: FemVue clearance, flibanserin approval, and more - Contemporary OB/GYN
Swing Trade: Why Femasys Inc. stock is a must watch in 20252025 Geopolitical Influence & Accurate Intraday Trading Signals - Улправда
What momentum indicators show for Femasys Inc. stockMarket Sentiment Review & Risk Managed Trade Strategies - Bölüm Sonu Canavarı
Why Femasys Inc. stock is rated strong buyJuly 2025 Momentum & Real-Time Volume Spike Alerts - Улправда
Femasys receives FDA clearance for FemVue Controlled diagnostic device By Investing.com - Investing.com Australia
How interest rate cuts could boost Femasys Inc. stockMarket Growth Review & Technical Entry and Exit Tips - Bölüm Sonu Canavarı
How strong is Femasys Inc. stock balance sheet2025 Trading Recap & Consistent Profit Focused Trading Strategies - DonanımHaber
Why Femasys Inc. stock is a must watch in 20252025 Market Sentiment & Growth Oriented Trade Recommendations - Улправда
What analyst consensus says on Femasys Inc. stockJuly 2025 Action & AI Powered Market Trend Analysis - DonanımHaber
Femasys Earnings Notes - Trefis
PharmaCyte Biotech (Nasdaq: PMCB) reports Q2 loss and details QCLS, Femasys deals - Stock Titan
Femasys Inc. Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - marketscreener.com
FDA clears FemVue Controlled for in-office tubal assessment - Contemporary OB/GYN
Femasys secures U.S. FDA clearance for next-generation Femvue diagnostic device - marketscreener.com
Femasys Gains FDA Clearance for FemVue Diagnostic Device - TipRanks
Femasys gains FDA clearance for FemVue diagnostic device - MSN
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - The Manila Times
Femasys Inc Secures FDA Clearance for FemVue Diagnostic Device - TradingView — Track All Markets
Femasys (NASDAQ: FEMY) secures FDA clearance for next-generation FemVue diagnostic - Stock Titan
Femasys receives FDA clearance for FemVue Controlled diagnostic device - Investing.com
Femasys Inc. Receives FDA Clearance for Innovative FemVue Controlled Device to Enhance Fallopian Tube Evaluation and Workflow Efficiency - Quiver Quantitative
New device could make fallopian tube testing simpler for fertility care - Stock Titan
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
Femasys Secures Major Order for FemBloc Launch - MSN
0.01%
1.19%
자본화:
|
볼륨(24시간):